Danaher Corporation
DHR-PA
New York Stock Exchange1,841.01
USD
- -
- -
Danaher Corporation
DHR-PA
(New York Stock Exchange)
Recent
price
1,841.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator headquartered in Washington, D.C. and founded in 1984, designs, manufactures, and markets professional medical, research, industrial, and commercial products and services worldwide; the company operates through three primary segments including biotechnology (approximately 28% of 2024 revenues), which provides bioprocessing solutions such as chromatography, filtration, single-use technologies, and tools for genomic medicines development; life sciences (approximately 31% of 2024 revenues), offering flow cytometry, lab automation, mass spectrometry including the 8600 ZenoTOF, microscopy, protein consumables, industrial filtration, and genomics tools to advance drug discovery, disease identification, and therapy testing; and diagnostics (approximately 41% of 2024 revenues), delivering core lab clinical instruments and consumables, molecular diagnostics via subsidiaries like Cepheid with flu detection kits and respiratory testing, acute care diagnostics, pathology diagnostics through Leica Biosystems, and software services for disease diagnosis. Danaher serves biopharmaceutical manufacturers, research institutions, healthcare providers, hospitals, and industrial facilities across the United States, China, Europe, and other regions with a workforce of approximately 79,000 associates, leveraging the Danaher Business System for continuous improvement and innovation supported by around $1.6 billion in annual R&D investments. Recent developments include a January 2025 investment partnership with Innovaccer Inc. through Danaher Diagnostics LLC and Danaher Ventures LLC to advance healthcare AI for unified patient records, precision diagnostics, and value-based care; a May 2025 diagnostic development and commercialization alliance with AstraZeneca, involving Leica Biosystems, to scale precision medicine with next-generation AI-powered diagnostics; executive appointments such as Martin Stumpe as Chief Technology and AI Officer in June 2025 and Jonathan Leiken as General Counsel in July 2025; a quarterly dividend increase to $0.32 per share announced in early 2025; and strong third-quarter 2025 results with 3.0% core revenue growth driven by bioprocessing momentum and Cepheid respiratory performance, alongside guidance for 3% to 6% core growth in 2026.